MXPA03011027A - Administracion oral de hormona paratiroides y calcitonina. - Google Patents

Administracion oral de hormona paratiroides y calcitonina.

Info

Publication number
MXPA03011027A
MXPA03011027A MXPA03011027A MXPA03011027A MXPA03011027A MX PA03011027 A MXPA03011027 A MX PA03011027A MX PA03011027 A MXPA03011027 A MX PA03011027A MX PA03011027 A MXPA03011027 A MX PA03011027A MX PA03011027 A MXPA03011027 A MX PA03011027A
Authority
MX
Mexico
Prior art keywords
calcitonin
parathyroid hormone
orally administering
pth
administering parathyroid
Prior art date
Application number
MXPA03011027A
Other languages
English (en)
Inventor
David Bateman Simon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03011027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA03011027A publication Critical patent/MXPA03011027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

Un metodo para administrar oralmente una hormona paratiroides, PTH, el cual comprende co-administrar oralmente a un paciente que necesite hormona paratiroides, una cantidad efectiva de una hormona paratiroides, y una cantidad efectiva de una calcitonina. El metodo de acuerdo con la invencion permite la administracion oral de hormona paratiroides sin los efectos secundarios de hipercalcemia, hipercalcuria, y nefrolitiasis.
MXPA03011027A 2001-06-01 2002-05-31 Administracion oral de hormona paratiroides y calcitonina. MXPA03011027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Publications (1)

Publication Number Publication Date
MXPA03011027A true MXPA03011027A (es) 2004-03-19

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011027A MXPA03011027A (es) 2001-06-01 2002-05-31 Administracion oral de hormona paratiroides y calcitonina.

Country Status (25)

Country Link
US (2) US20040186050A1 (es)
EP (1) EP1397156B1 (es)
JP (2) JP5073153B2 (es)
KR (3) KR101320817B1 (es)
CN (2) CN101837120A (es)
AT (1) ATE356631T1 (es)
AU (2) AU2002344371B2 (es)
BR (1) BRPI0209748B1 (es)
CA (1) CA2446929C (es)
CO (1) CO5540323A2 (es)
CZ (1) CZ307145B6 (es)
DE (1) DE60218842T2 (es)
EC (1) ECSP034858A (es)
ES (1) ES2282436T3 (es)
HU (1) HU229613B1 (es)
IL (2) IL158777A0 (es)
MX (1) MXPA03011027A (es)
NO (1) NO330093B1 (es)
NZ (1) NZ529439A (es)
PL (1) PL211976B1 (es)
PT (1) PT1397156E (es)
RU (1) RU2300392C2 (es)
SK (1) SK287697B6 (es)
WO (1) WO2002098453A2 (es)
ZA (1) ZA200308625B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101320817B1 (ko) 2001-06-01 2013-10-21 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
RU2322256C2 (ru) 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AR058053A1 (es) 2005-09-19 2008-01-23 Toole Doris C O Formas cristalinas polimorficas de la sal de di- sodio del acido n- (5 -clorosaliciloil)-8- aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CA2626933C (en) * 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
CN101952241B (zh) 2007-11-02 2014-06-11 艾米斯菲尔技术公司 治疗维生素b12缺乏的方法
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2151742C (en) * 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
EP1093819B1 (en) 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
WO2001032201A2 (en) 1999-10-29 2001-05-10 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
KR101320817B1 (ko) 2001-06-01 2013-10-21 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
RU2322256C2 (ru) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Also Published As

Publication number Publication date
AU2006225157B2 (en) 2009-04-23
US8153587B2 (en) 2012-04-10
RU2300392C2 (ru) 2007-06-10
IL158777A (en) 2012-06-28
AU2002344371B2 (en) 2006-06-29
CA2446929A1 (en) 2002-12-12
WO2002098453A2 (en) 2002-12-12
RU2003136733A (ru) 2005-05-20
DE60218842T2 (de) 2007-12-20
US20080119411A1 (en) 2008-05-22
EP1397156A2 (en) 2004-03-17
ECSP034858A (es) 2004-01-28
CZ307145B6 (cs) 2018-02-07
EP1397156B1 (en) 2007-03-14
KR20090116836A (ko) 2009-11-11
JP5073153B2 (ja) 2012-11-14
ES2282436T3 (es) 2007-10-16
CO5540323A2 (es) 2005-07-29
PT1397156E (pt) 2007-05-31
BRPI0209748B1 (pt) 2015-11-24
CN1512892A (zh) 2004-07-14
KR20120065429A (ko) 2012-06-20
KR20040007617A (ko) 2004-01-24
HU229613B1 (en) 2014-03-28
CA2446929C (en) 2013-04-09
US20040186050A1 (en) 2004-09-23
NO330093B1 (no) 2011-02-14
DE60218842D1 (de) 2007-04-26
SK287697B6 (sk) 2011-06-06
HUP0400120A3 (en) 2012-09-28
SK14752003A3 (sk) 2004-06-08
CZ20033232A3 (cs) 2004-06-16
AU2006225157A1 (en) 2006-10-19
PL211976B1 (pl) 2012-07-31
WO2002098453A3 (en) 2003-07-31
CN101837120A (zh) 2010-09-22
NO20035133L (no) 2003-11-18
JP2010189423A (ja) 2010-09-02
NZ529439A (en) 2005-11-25
NO20035133D0 (no) 2003-11-18
IL158777A0 (en) 2004-05-12
BR0209748A (pt) 2004-07-27
ATE356631T1 (de) 2007-04-15
JP2005500277A (ja) 2005-01-06
HUP0400120A2 (hu) 2005-04-28
PL364089A1 (en) 2004-12-13
KR101320817B1 (ko) 2013-10-21
ZA200308625B (en) 2004-07-13

Similar Documents

Publication Publication Date Title
IL158777A0 (en) Orally administering parathyroid hormone and calcitonin
JP2002523375A5 (es)
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
DE69831869D1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
GEP20053473B (en) High Potency Dihydroergotamine Compositions
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
IL159714A0 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
AU6788701A (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
PL348202A1 (en) Pharmaceutically active composition and dispensing device
WO2001066102A3 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
CA2403674A1 (en) The use of t3 for treating congestive heart failure
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
MD1783F1 (en) Method of epilepsy treatment
UA36137A (uk) Спосіб лікування хворих на хронічне легеневе серце
ECSP003419A (es) Terapia para melanomas
MD1963F1 (en) Method of treatment of the chronic recurrent aphthous stomatitis

Legal Events

Date Code Title Description
FG Grant or registration